Effect of an early dose of measles vaccine on morbidity between 18 weeks and 9 months of age: A randomized, controlled trial in Guinea-Bissau

Journal of Infectious Diseases

Volumn 215, Issue 8, 2017, Pages 1188-1196

  Do, Vu An ^a,b   Biering Sørensen, Sofie ^a,b   Fisker, Ane Bærent ^a,b   Balé, Carlito ^b   Rasmussen, Stine Møller ^a,b   Christensen, Lone Damkjær ^a,b   Jensen, Kristoffer Jarlov ^a,c   Martins, Cesário ^b   Aaby, Peter ^b   Benn, Christine Stabell ^a,d  

^a STATENS SERUM INSTITUT   (Denmark)

^b Studies of the Epidemiology of Epilepsy in Demographic Surveillance Systems   (Guinea-Bissau)

^c TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^d UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Adverse events; Heterologous immunity; Measles vaccine; Morbidity; Non specific effects of vaccines; Pediatric

Indexed keywords

MEASLES VACCINE;

CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; FEMALE; GUINEA-BISSAU; HETEROLOGOUS IMMUNITY; HOME VISIT; HUMAN; IMMUNIZATION; INFANT; MALE; MEASLES; MORBIDITY; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; RANDOMIZED CONTROLLED TRIAL; STATISTICS AND NUMERICAL DATA; VACCINATION; VOMITING;

DIARRHEA; FEMALE; GUINEA-BISSAU; HOUSE CALLS; HUMANS; IMMUNITY, HETEROLOGOUS; IMMUNIZATION SCHEDULE; INFANT; MALE; MEASLES; MEASLES VACCINE; MORBIDITY; PROPORTIONAL HAZARDS MODELS; VACCINATION; VOMITING;

EID: 85026723515     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiw512     Document Type: Article

References (29)

1. Aaby P, Martins C, Garly ML, et al. Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised controlled trial. BMJ 2010; 341:c6495–c.
2. Aaby P, Bhuiya A, Nahar L, Knudsen K, de Francisco A, Strong M. The survival benefit of measles immunization may not be explained entirely by the prevention of measles disease: a community study from rural Bangladesh. Int J Epidemiol 2003; 32:106–16.
3. Aaby P, Samb B, Andersen M, Simondon F. No long-term excess mortality after measles infection: a community study from Senegal. Am J Epidemiol 1996; 143:1035–41.
4. Lund N, Andersen A, Hansen AS, et al. The effect of oral polio vaccine at birth on infant mortality: a randomized trial. Clin Infect Dis 2015; 61:1504–11.
5. Aaby P, Benn C, Nielsen J, Lisse IM, Rodrigues A, Ravn H. Testing the hypothesis that diphtheria-tetanus-pertussis vaccine has negative non-specific and sex-differential effects on child survival in high-mortality countries. BMJ Open 2012; 2.pii:e000707. doi:10.1136/bmjopen-2011-000707.
6. Aaby P, Ravn H, Benn CS. The WHO review of the possible non-specific effects of diphtheria-tetanus-Pertussis vaccine. Pediatr Infect Dis J 2016; 35:1247–57.
7. Expanded programme on immunization. The optimal age for measles immunization. Wkly Epidemiol Rec 1982; 57:89e91 1982.
8. Martins CL, Benn CS, Andersen A, et al. A randomized trial of a standard dose of Edmonston-Zagreb measles vaccine given at 4.5 months of age: effect on total hospital admissions. J Infect Dis 2014; 209:1731–8.
9. Veirum JE, Sodemann M, Biai S, et al. Routine vaccinations associated with divergent effects on female and male mortality at the paediatric ward in Bissau, Guinea-Bissau. Vaccine 2005; 23:1197–204.
10. UNICEF, WHO. Immunization summary—a statistical reference containing data through 2010. 2012:71.
11. Plotkin SA, Orenstein WA, Offit PA. Vaccines. 5th ed. Philadelphia, Pennsylvania: Elsevier Saunders, 2008:353–98.
12. Fisker AB, Bale C, Jorgensen MJ, et al. High-dose vitamin A supplementation administered with vaccinations after 6 months of age: sex-differential adverse reactions and morbidity. Vaccine 2013; 31:3191–8.
13. Aaby P, Garly ML, Nielsen J, et al. Increased female-male mortality ratio associated with inactivated polio and diphtheria-tetanus-pertussis vaccines: Observations from vaccination trials in Guinea-Bissau. Pediatr Infect Dis J 2007; 26:247–52.
14. Aaby P, Martins CL, Garly ML, et al. Measles vaccination in the presence or absence of maternal measles antibody: impact on child survival. Clin Infect Dis 2014; 59:484–92.
15. Mina MJ, Metcalf CJ, de Swart RL, Osterhaus AD, Grenfell BT. Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality. Science 2015; 348:694–9.
16. SAGE non-specific effects of vaccines Working Group. Evidence based recommendations on non-specific effects of BCG, DTP-containing and measles-containing vaccines on mortality in children under 5 years of age. Background paper for SAGE discussions. World Health Organization, 2014.
17. Sorup S, Benn CS, Poulsen A, Krause TG, Aaby P, Ravn H. Live vaccine against measles, mumps, and rubella and the risk of hospital admissions for nontargeted infections. JAMA 2014; 311:826–35.
18. Aaby P, Ibrahim SA, Libman MD, Jensen H. The sequence of vaccinations and increased female mortality after high-titre measles vaccine: trials from rural Sudan and Kinshasa. Vaccine 2006; 24:2764–71.
19. Martins C, Bale C, Garly ML, et al. Girls may have lower levels of maternal measles antibodies and higher risk of subclinical measles infection before the age of measles vaccination. Vaccine 2009; 27:5220–5.
20. Kleinnijenhuis J, Quintin J, Preijers F, et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci USA 2012; 109: 17537–42.
21. Ovsyannikova IG, Reid KC, Jacobson RM, Oberg AL, Klee GG, Poland GA. Cytokine production patterns and antibody response to measles vaccine. Vaccine 2003; 21:3946–53.
22. Smedman L, Joki A, da Silva AP, Troye-Blomberg M, Aronsson B, Perlmann P. Immunosuppression after measles vaccination. Acta Paediatr 1994; 83:164–8.
23. Hussey GD, Goddard EA, Hughes J, et al. The effect of Edmonston-Zagreb and Schwarz measles vaccines on immune response in infants. J Infect Dis 1996; 173:1320–6.
24. Schnorr JJ, Cutts FT, Wheeler JG, et al. Immune modulation after measles vaccination of 6–9 months old Bangladeshi infants. Vaccine 2001; 19:1503–10.
25. Rager-Zisman B, Bazarsky E, Skibin A, et al. Differential immune responses to primary measles-mumps-rubella vaccination in Israeli children. Clin Diagn Lab Immunol 2004; 11:913–8.
26. Ziola B, Smith RH. T cell cross-reactivity among viruses of the paramyxoviridae. Viral Immunol 1987; 1:111–9.
27. Weber MW, Milligan P, Sanneh M, et al. An epidemiological study of RSV infection in the Gambia. Bull World Health Organ 2002; 80:562–8.
28. Sorup S, Benn CS, Stensballe LG, Aaby P, Ravn H. Measles-mumps-rubella vaccination and respiratory syncytial virus-associated hospital contact. Vaccine 2015; 33:237–45.
29. Measles vaccines: WHO position paper. Wkly Epidemiol Rec 2009; 84:349–60.